<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694118</url>
  </required_header>
  <id_info>
    <org_study_id>10840098-604.01.01-E.66352</org_study_id>
    <nct_id>NCT04694118</nct_id>
  </id_info>
  <brief_title>Comparison of the Effectiveness of Walking Back Exercises and Rebound Therapy in Cerebral Palsy Rehabilitation</brief_title>
  <official_title>Comparison of the Effectiveness of Walking Back Exercises and Rebound Therapy in Cerebral Palsy Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medipol University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medipol University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study:&#xD;
&#xD;
      To investigate the effect of walking back exercises and rebound therapy on muscle strength,&#xD;
      functionality, balance and aerobic capacity in children with CP Implication for&#xD;
      rehabilitation:Determining the effects of rehabilitative interventions (back and forth&#xD;
      walking exercises and rebound therapy) to be applied in children with CP with objective&#xD;
      measurement methods (muscle US, tetrax balance system) and evaluating the effects of the&#xD;
      results on functionality and respiratory parameters&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:&#xD;
&#xD;
      Being diagnosed with SP To be in the age range of 6-15 years, where effective communication&#xD;
      can be provided in evaluation and treatment processes and when walking begins to mature&#xD;
      Having adequate communication skills Being on level I or level II according to GMFM No&#xD;
      impairment in visual functions in terms of not affecting postural control responses, Children&#xD;
      with family consent&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Application of the evaluation methods specified at the beginning of the study to all 30&#xD;
      patients with CP who were randomly divided into 2 groups.&#xD;
&#xD;
      Re-evaluations were planned 8 weeks after the first evaluation of all cases who were&#xD;
      continuing with structured neurodevelopmental treatment programs. In addition to the ongoing&#xD;
      structured neurodevelopmental treatment programs; Group 1: 12 weeks / 3 days 20 minutes&#xD;
      walking back exercises on normal ground, Group 2: Rebound therapy exercises, which are&#xD;
      arranged according to the functional levels of the cases, will be applied in 12 weeks / 3&#xD;
      days for 20 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomise controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in muscle volume</measure>
    <time_frame>one measurement at the beginning of the study, second measurement 8 weeks later, 3rd measurement at 12th week following</time_frame>
    <description>ultrasonic imaging</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cerebral Palsy, Spastic</condition>
  <arm_group>
    <arm_group_label>15 hemiparetic cerebral palsy,walking back group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 hemiparetic cerebral palsy,rebound therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rebound therapy</intervention_name>
    <description>3 days a week in 12 weeks</description>
    <arm_group_label>15 hemiparetic cerebral palsy,rebound therapy group</arm_group_label>
    <arm_group_label>15 hemiparetic cerebral palsy,walking back group</arm_group_label>
    <other_name>walking back exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being diagnosed with hemiparetic SP To be in the age range of 6-15 years, where&#xD;
             effective communication can be provided in evaluation and treatment processes and when&#xD;
             walking begins to mature Having adequate communication skills Being on level I or&#xD;
             level II according to KMFSS No impairment in visual functions in terms of not&#xD;
             affecting postural control responses, Children with family consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Orthopedic surgery and / or botulinum toxin-A application for the lower extremity in&#xD;
             the last 6 months Being at level III, level IV or level V according to KMFSS Severe&#xD;
             convulsion situations that cannot be controlled with drugs Presence of a medical&#xD;
             condition that prevents participation in the study Congenital malformation conditions&#xD;
             accompanying CP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ulku atasoy, msc.pt</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhD student</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>devrim tarakcı, assoc.prof.</last_name>
    <phone>4448544</phone>
    <phone_ext>1890</phone_ext>
    <email>dtarakci@medipol.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Umran medical center</name>
      <address>
        <city>İstanbul</city>
        <state>Uskudar</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ülkü atasoy, msc.pt</last_name>
      <phone>+905435796261</phone>
      <email>ulkuatasoy2017@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulku Atasoy</name>
      <address>
        <city>İstanbul</city>
        <state>Ümraniye</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ulku atasoy, msc.pt</last_name>
      <phone>+905435796261</phone>
      <email>ulkuatasoy2017@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 1, 2021</study_first_submitted>
  <study_first_submitted_qc>January 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medipol University Hospital</investigator_affiliation>
    <investigator_full_name>ulkuatasoy2017</investigator_full_name>
    <investigator_title>Msc.physiotherapist</investigator_title>
  </responsible_party>
  <keyword>Cerebral palsy,</keyword>
  <keyword>neurodevelopmental therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication).</ipd_time_frame>
    <ipd_access_criteria>Users and editors with journal memberships published for pubmed users</ipd_access_criteria>
    <ipd_url>https://pubmed.ncbi.nlm.nih.gov/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

